SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Modelling trajectories and mechanisms of childhood hip dysplasia

The HIPSTAR project aims to identify and prevent hip dysplasia in children to reduce the risk of developing osteoarthritis in adulthood by studying growth patterns and causal factors.

Subsidie
€ 2.499.373
2023

Projectdetails

Introduction

With 40 million patients in Europe, osteoarthritis (OA) is the most common chronic and disabling disease. OA is incurable, and symptomatic treatments have limited effect. Therefore, prevention by identifying and targeting asymptomatic persons that develop a clear OA risk factor is sorely needed.

Risk Factors

Hip dysplasia is the strongest risk factor for hip OA. It is a condition of mechanical instability of the hip caused by insufficient coverage of the femoral head (ball) by a shallow or obliquely oriented acetabulum (socket). This results in high cartilage stress and subsequent hip OA.

Current Screening Practices

In Europe, we screen for developmental hip dysplasia in infants (prevalence 2%), enabling early treatment. However, we discovered that hip dysplasia can (further) develop during skeletal maturation and thus remains unrecognized. In 1100 Dutch 9-year-old children, we found a 6% and 26% prevalence of marked and mild hip dysplasia, respectively.

Developmental Insights

Hip dysplasia can be influenced until the stage where hip growth plates close at about age 13.

Proposed Research Program

I propose a novel research program (HIPSTAR) where I will uniquely unravel the mechanisms behind late childhood hip dysplasia in order to pave the way for devising preventive measures that reduce the prevalence of adult hip dysplasia and, thus, hip OA.

Research Methodology

In a birth cohort of 8000 children (followed from fetal life until adulthood), I will:

  1. Build a 5D growth model on how hip shape develops over time from age 2-18 years.
  2. Gain novel knowledge regarding causal factors of dysplastic growth and whether there are various phenotypes that have different underlying mechanisms.
  3. Study how and when dysplastic growth will already impact the integrity of the young adult joint and discover very early signs of joint aberration leading to OA.

Computational Analysis

Finally, in a computational model, I will test the influence of loading factors on dysplastic growth mechanistically and provide detailed information regarding the potential remedial options.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.499.373
Totale projectbegroting€ 2.499.373

Tijdlijn

Startdatum1-1-2023
Einddatum31-12-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMpenvoerder
  • TECHNISCHE UNIVERSITEIT DELFT

Land(en)

Netherlands

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

reGeneRative bone Implant for the treatment of hip dysPlasia

GRIP aims to revolutionize hip dysplasia treatment with personalized, 3D-printed regenerative bone implants, enhancing integration and reducing invasiveness compared to current methods.

ERC Proof of...€ 150.000
2022
Details

In Silico Trials for Cartilage Regenerative Medicine Applications

The INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials.

ERC Consolid...€ 2.212.385
2023
Details

Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life course

OBESE-EMBRYO aims to improve cardiovascular health in future generations by targeting the embryonic obesogenic environment in overweight and obese parents-to-be through innovative, evidence-based interventions.

ERC Starting...€ 1.499.998
2025
Details

Development of an instrumented hammer to assess the stability of hip implant during surgery: assessment of the commercial feasibility

Impactor aims to develop a decision support system for assessing hip implant stability using an instrumented orthopedic hammer, enhancing surgical strategies and commercial potential in orthopedic surgery.

ERC Proof of...€ 150.000
2022
Details

Disruptive Therapies for the long-term relief of Osteoarthritis Pain

The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.

ERC Consolid...€ 1.998.885
2023
Details
ERC Proof of...

reGeneRative bone Implant for the treatment of hip dysPlasia

GRIP aims to revolutionize hip dysplasia treatment with personalized, 3D-printed regenerative bone implants, enhancing integration and reducing invasiveness compared to current methods.

ERC Proof of Concept
€ 150.000
2022
Details
ERC Consolid...

In Silico Trials for Cartilage Regenerative Medicine Applications

The INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials.

ERC Consolidator Grant
€ 2.212.385
2023
Details
ERC Starting...

Impact of the embryonic obesogenic environment on programming of cardiovascular diseases across the life course

OBESE-EMBRYO aims to improve cardiovascular health in future generations by targeting the embryonic obesogenic environment in overweight and obese parents-to-be through innovative, evidence-based interventions.

ERC Starting Grant
€ 1.499.998
2025
Details
ERC Proof of...

Development of an instrumented hammer to assess the stability of hip implant during surgery: assessment of the commercial feasibility

Impactor aims to develop a decision support system for assessing hip implant stability using an instrumented orthopedic hammer, enhancing surgical strategies and commercial potential in orthopedic surgery.

ERC Proof of Concept
€ 150.000
2022
Details
ERC Consolid...

Disruptive Therapies for the long-term relief of Osteoarthritis Pain

The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.

ERC Consolidator Grant
€ 1.998.885
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Bestrijding Artrose met Operatie Robots

Dit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren.

Mkb-innovati...€ 20.000
2021
Details

Development of a Complete Triple Action Injectable Treatment for Osteoarthritis

Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.

EIC Transition€ 2.398.115
2022
Details

SmartForward 4 Health

Het project ontwikkelt het interactieve trainingssysteem SmartForward 4 Health om heuprevalidatie efficiënter, leuker en goedkoper te maken met behulp van digitale technologieën.

Mkb-innovati...€ 151.472
2021
Details

INTELLECTUALS

Dit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis.

1.1 - Het ve...€ 479.529
2024
Details

SmartForward 4 Health

SmartForward 4 Health ontwikkelt een interactief trainingssysteem voor efficiëntere en leukere heuprevalidatie met digitale technologieën.

Mkb-innovati...€ 151.472
2021
Details
Mkb-innovati...

Bestrijding Artrose met Operatie Robots

Dit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren.

Mkb-innovatiestimulering Topsectoren Haalbaarheid
€ 20.000
2021
Details
EIC Transition

Development of a Complete Triple Action Injectable Treatment for Osteoarthritis

Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.

EIC Transition
€ 2.398.115
2022
Details
Mkb-innovati...

SmartForward 4 Health

Het project ontwikkelt het interactieve trainingssysteem SmartForward 4 Health om heuprevalidatie efficiënter, leuker en goedkoper te maken met behulp van digitale technologieën.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 151.472
2021
Details
1.1 - Het ve...

INTELLECTUALS

Dit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis.

1.1 - Het versterken van de onderzoeks- en innovatiecapaciteit en de invoering van geavanceerde technologieën
€ 479.529
2024
Details
Mkb-innovati...

SmartForward 4 Health

SmartForward 4 Health ontwikkelt een interactief trainingssysteem voor efficiëntere en leukere heuprevalidatie met digitale technologieën.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 151.472
2021
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.